Jindrich Kopecek and Jiyuan Yang have designed a new immune checkpoint inhibitor
Jindrich Kopecek & Jiyuan Yang have designed a new immune checkpoint inhibitor “Multivalent Polymer-Peptide Antagonist” which was accepted by the National Characterization Laboratory (NCL) at the Frederick National Laboratory for Cancer Research (NCI) for preclinical evaluation. The award will focus on combination immunotherapy and chemotherapy of breast cancer. The lab will provide the conjugates and all testing at NCL will be free of charge. Congratulations on this unique collaboration!
